William Tong
Lawyers
Filters
CellCentric $220 million Series D financing round
We advised Venrock Healthcare Capital Partners
MSCI acquisition of Compass Financial Technologies
We advised MSCI on the acquisition
LXO Group hybrid capital acquisition financing
We advised Hayfin Capital Management on its hybrid capital investment in LXO Group
bit.bio $50 million Series C equity financing
We are advising the company on the funding round
Beacon Therapeutics $75 million Series C financing round
We advised Forbion on its participation in the financing round
Natura sale of Avon International to Regent
We are advising Natura on the sale
Fever acquisition of DICE
We are advising Fever on the acquisition
Telemos Capital investment partnership with Helios Global Group
We are advising Telemos Capital on the transaction
Stellex Capital Management acquisition of Fox Brothers Holdings Group
We advised Stellex Capital Management on the acquisition
MSCI acquisition of Foxberry
We are advising MSCI on the acquisition